Skip to main content
. 2017 Nov 15;8(67):111110–111118. doi: 10.18632/oncotarget.22624

Figure 3. Effect of CHMFL-KIT-031 in the BaF3-TEL-KIT-V559D inoculated mouse model.

Figure 3

Female nu/nu mice bearing established BaF3-TEL-KIT-V559D tumor allagraft model were treated with CHMFL-KIT-031 at 25, 50 and 100 mg/kg/d dosages or vehicle. Daily IP administration was initiated when BaF3-TEL-KIT-V559D tumors had reached a size of 200 to 400 mm3. Each group contained five animals. Data, mean ± SEM. (A) Body weight and (B) Tumor size measurements from BaF3-TEL-KIT-V559D allagraft mice after 10 days CHMFL-KIT-031 administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 0, 25, 50 and 100 mg/kg/d CHMFL-KIT-031 or vehicle treatment. (D) Comparison of the final tumor weights in each group after 10-day treatment period of CHMFL-KIT-031. Numbers in columns indicate the mean tumor weight in each group. ns, p>0.05, (*) p<0.05, (**) p<0.01. (E) Western blot analysis of CHMFL-KIT-031 on KIT signaling pathways in the tumor tissues after 10-day treatment period.